RTX001

RTX001 is an engineered, autologous regenerative macrophage cell therapy developed by Resolution Therapeutics for the treatment of decompensated liver cirrhosis and end-stage liver disease. The therapy involves converting a patient's own white blood cells into macrophages that are further engineered to enhance their anti-fibrotic and anti-inflammatory properties. These modified macrophages are designed to promote tissue regeneration and reduce fibrosis in damaged livers. RTX001 is administered as a dispersion for infusion (intravenous). The product candidate leverages therapeutic genes known to be expressed in macrophages, aiming for superior efficacy and durability compared to non-engineered cells. Clinical development includes Phase 1/2 studies (EMERALD study) focusing on safety and major clinical events such as all-cause mortality[1][2][3][4][6][7][8].

Other names

autologous monocyte-derived macrophagesmacrophage cell therapy